HBM HEALTHCARE INVESTMENTS AG (FRA:CH001262) Successful IPO of HBM portfolio company Mineralys Therapeutics
Transparency directive : regulatory news
|
HBM Healthcare Investments AG
/ Key word(s): IPO
Mineralys Therapeutics (Nasdaq: MLYS), a previously private company in the portfolio of HBM Healthcare Investments, successfully completed its IPO last Friday. The company placed 12 million new shares at a price of USD 16.00 per share, raising USD 192 million in new capital. On the first day of trading, the share price rose to USD 18.44 (+15.25%). HBM Healthcare Investments has invested a total of USD 19 million in the company in two private financing rounds since February 2021. The investment was previously valued at USD 27 million. In addition, HBM Healthcare Investments also participated in the IPO. Based on Friday's closing share price, the investment is valued at USD 57 million. This results in an increase of the net asset value per HBM-share (NAV) of CHF 3.60. Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's lead product candidate, lorundrostat, is a orally administered, highly selective aldosterone synthase inhibitor (ASI) that is initially developed for the treatment of patients with hypertension. Contact
End of Media Release |
| Language: | English |
| Company: | HBM Healthcare Investments AG |
| Bundesplatz 1 | |
| 6300 Zug | |
| Switzerland | |
| Phone: | +41438887171 |
| Fax: | +41438887172 |
| E-mail: | info@hbmhealthcare.com |
| Internet: | https://www.hbmhealthcare.com |
| ISIN: | CH0012627250 |
| Valor: | 1262725 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1557751 |
| End of News | EQS News Service |
|
|
1557751 13.02.2023 CET/CEST